McDonald Gabrielle, Medina Carlos O, Pilichowska Monika, Kearney John F, Shinkura Reiko, Selsing Erik, Wortis Henry H, Honjo Tasuku, Imanishi-Kari Thereza
Department of Integrative Physiology and Pathobiology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, United States.
Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, MA, United States.
Front Immunol. 2017 Sep 13;8:1094. doi: 10.3389/fimmu.2017.01094. eCollection 2017.
564Igi mice have knocked-in immunoglobulin (Ig) heavy (H) and light (L) chain genes that encode an autoantibody recognizing RNA. Previously, we showed that these mice produce pathogenic IgG autoantibodies when activation-induced deaminase (AID) is expressed in pre-B and immature B cells but not when it is expressed only in mature B cells. AID has two functions; it is necessary for somatic hypermutation (SHM) and class switch recombination (CSR). To determine the role of each of these functions in the generation of pathogenic autoantibodies, we generated 564Igi mice that carry a mutant AID-encoding gene, (), which is capable of promoting CSR but not SHM. We found that 564Igi mice secreted class-switched antibodies (Abs) at levels approximately equal to 564Igi mice. However, compared to 564Igi mice, 564Igi mice had increased pathogenic IgG Abs and severe systemic lupus erythematosus-like disease, including, glomerulonephritis, and early death. We suggest that in 564Igi mice SHM by AID changes Ig receptors away from self reactivity, thereby mitigating the production of autoantibody, providing a novel mechanism of tolerance.
564Igi小鼠的免疫球蛋白(Ig)重链(H)和轻链(L)基因被敲入,这些基因编码一种识别RNA的自身抗体。此前,我们发现,当激活诱导的脱氨酶(AID)在前B细胞和未成熟B细胞中表达时,这些小鼠会产生致病性IgG自身抗体,但仅在成熟B细胞中表达时则不会。AID有两种功能;它是体细胞高频突变(SHM)和类别转换重组(CSR)所必需的。为了确定这些功能各自在致病性自身抗体产生中的作用,我们培育了携带突变AID编码基因()的564Igi小鼠,该基因能够促进CSR但不能促进SHM。我们发现,564Igi小鼠分泌的类别转换抗体(Abs)水平与564Igi小鼠大致相当。然而,与564Igi小鼠相比,564Igi小鼠的致病性IgG Abs增加,且患有严重的系统性红斑狼疮样疾病,包括肾小球肾炎,并过早死亡。我们认为,在564Igi小鼠中,AID介导的SHM使Ig受体远离自身反应性,从而减少自身抗体的产生,提供了一种新的耐受机制。